Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00195741 · ClinicalTrials.gov registry record · Phase 3
The Safety and Efficacy of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis: A Study in Adolescents
A Phase 3 study of Migraine, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT00195741 is a Phase 3 study of Migraine that has completed, run by Abbott. The registered enrollment target is 300 participants, below the 355-participant average among 102 other Migraine trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00195741, a Phase 3 study of Migraine, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether Depakote ER is safe and effective in the reduction of occurrence of migraine headaches in adolescents.
Conditions Studied
Interventions
- DRUG divalproex sodium
Study Locations (1)
Illinois
- Global Medical Information - Abbott - North Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2003-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00195741
The ClinicalTrials.gov registry entry for NCT00195741 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 355-participant average among 102 other Migraine trials with a reported enrollment target (15% lower). The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which divalproex sodium is the first listed.
NCT00195741 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00195741 about?
NCT00195741 is a clinical study titled "The Safety and Efficacy of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis: A Study in Adolescents". The purpose of this study is to determine whether Depakote ER is safe and effective in the reduction of occurrence of migraine headaches in adolescents.
What is the current status of trial NCT00195741?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2003-05.
What conditions does trial NCT00195741 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT00195741?
The interventions under investigation include: divalproex sodium (DRUG).
Who is sponsoring clinical trial NCT00195741?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00195741 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.